Nasdaq

Clairity, Myriad Genetics, and MagView Launch the First Integrated AI and Genetic Risk Platform for Personalized Breast Health

For the first time, clinicians and patients will have access to an integrated view of genotype (Myriad’s MyRisk with RiskScore test) and phenotype (Clairity Breast) through MagView’s Luminary Risk ...
Investing

Clairity, Myriad Genetics, MagView partner on breast cancer risk tools

BOSTON/SALT LAKE CITY/FULTON - Clairity, Myriad Genetics, Inc. (NASDAQ:MYGN), and MagView announced Tuesday a collaboration aimed at improving breast cancer risk assessment by integrating their ...
Finanznachrichten

Myriad Genetics, Inc.: Clairity, Myriad Genetics, and MagView Launch the First Integrated AI and Genetic Risk Platform for Personalized Breast Health

BOSTON and SALT LAKE CITY and FULTON, Md., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Clairity, Myriad Genetics, Inc. (NASDAQ: MYGN), and MagView, today announced a joint collaboration in an effort to identify ...